Literature DB >> 19415466

Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant.

Ming-Hsi Huang1, Chiung-Yi Huang, Shu-Pei Lien, Syuan-Yi Siao, Ai-Hsiang Chou, Hsin-Wei Chen, Shih-Jen Liu, Chih-Hsiang Leng, Pele Chong.   

Abstract

PURPOSE: To enhance the water affinity of W/O emulsion-adjuvanted vaccines, we used three bioresorbable polymers named PEG-b-PLA, PEG-b-PCL, and PEG-b-PLACL as hydrophilic emulsifier to stabilize the interfaces between the oily Montanide ISA 51 adjuvant and the antigen media.
METHODS: Polymers were synthesized by ring-opening polymerization of lactide and/or epsilon-caprolactone in the presence of monomethoxy PEG. (1)H NMR and GPC data showed that obtained polymers consisted of 70 wt.% hydrophilic PEG block and 30 wt.% lipophilic PLA, PCL, PLACL block with molecular weights of 7,000.
RESULTS: The polymer-stabilized ISA51 emulsions have high affinity to water, such that the stock of antigen-encapsulating emulsion could be re-dispersed into PBS before injection, thus yielding stable and injectable W/O/W emulsion nanoparticles. Immunogenicity studies showed that PEG-b-PLACL/ISA51/PBS-formulated ovalbumin with only 5% of ISA51 oily adjuvant could induce the same level of antibody titers as those induced by PBS/ISA51-formulated ovalbumin.
CONCLUSIONS: The novel multi-phase emulsions increase fluidity and conceptually diminish local reactions with respect to the W/O type vaccines produced from the same oil. These features are of great interest for applications in candidate vaccine delivery, especially for further optimization of alternative immunization routes, such as intramuscular, transdermal or mucosal administration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415466     DOI: 10.1007/s11095-009-9898-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.

Authors:  A Podda
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

2.  Development of adjuvant-active nonionic block copolymers.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-07-06       Impact factor: 15.470

3.  Adjuvant activity of incomplete Freund's adjuvant.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-07-06       Impact factor: 15.470

4.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.

Authors:  Jerome Aucouturier; L Dupuis; S Deville; S Ascarateil; V Ganne
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

Review 5.  Targeting the innate immune response with improved vaccine adjuvants.

Authors:  Achal Pashine; Nicholas M Valiante; Jeffrey B Ulmer
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

6.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

Review 7.  Advances in vaccine adjuvants.

Authors:  M Singh; D O'Hagan
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

8.  Relation of detergent HLB number to solubilization and stabilization of D-alanine carboxypeptidase from Bacillus subtilis membranes.

Authors:  J N Umbreit; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

9.  Poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles.

Authors:  Geneviève Gaucher; Monika Poreba; François Ravenelle; Jean-Christophe Leroux
Journal:  J Pharm Sci       Date:  2007-07       Impact factor: 3.534

10.  Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines.

Authors:  Chun Wang; Qing Ge; David Ting; David Nguyen; Hui-Rong Shen; Jianzhu Chen; Herman N Eisen; Jorge Heller; Robert Langer; David Putnam
Journal:  Nat Mater       Date:  2004-02-15       Impact factor: 43.841

View more
  6 in total

1.  Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice.

Authors:  Ming-Hsi Huang; Su-Chen Lin; Chia-Hsin Hsiao; Hsin-Ju Chao; Hung-Ren Yang; Chien-Chun Liao; Po-Wei Chuang; Huang-Pi Wu; Chiung-Yi Huang; Chih-Hsiang Leng; Shih-Jen Liu; Hsin-Wei Chen; Ai-Hsiang Chou; Alan Yung-Chih Hu; Pele Chong
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 2.  Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.

Authors:  Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2013-02       Impact factor: 4.118

3.  Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.

Authors:  Chen-Yi Chiang; Ming-Hsi Huang; Chun-Hsiang Hsieh; Mei-Yu Chen; Hsueh-Hung Liu; Jy-Ping Tsai; Yi-Shiuan Li; Ching-Yun Chang; Shih-Jen Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  PLoS Negl Trop Dis       Date:  2012-05-15

4.  Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.

Authors:  Md Mohosin Rana
Journal:  J Biomater Sci Polym Ed       Date:  2021-04-14       Impact factor: 3.517

5.  Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy.

Authors:  Chung-Hsiung Huang; Chiung-Yi Huang; Chih-Ping Cheng; Shih-Hsiung Dai; Hsin-Wei Chen; Chih-Hsiang Leng; Pele Chong; Shih-Jen Liu; Ming-Hsi Huang
Journal:  Sci Rep       Date:  2016-11-09       Impact factor: 4.379

6.  Bioresorbable hydrogels prepared by photo-initiated crosslinking of diacrylated PTMC-PEG-PTMC triblock copolymers as potential carrier of antitumor drugs.

Authors:  Yuandou Wang; Laishun Xi; Baogang Zhang; Qingzhen Zhu; Feng Su; Katarzyna Jelonek; Arkadiusz Orchel; Janusz Kasperczyk; Suming Li
Journal:  Saudi Pharm J       Date:  2020-01-31       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.